| Name | Title | Contact Details |
|---|
Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.
HCS designs and delivers technology driven therapy management to improve patient initiation, adherence, and persistence. Since 2008, HCS has worked with biopharma brand teams who want to deliver personalized, omni-channel programming with measured outcomes.
Bio Direct is a Taunton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AXXAM is a Milford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RTI Products is a Amesbury, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.